Teva Pharmaceutical Industries Ltd. is expected to soon face generic competition for its thrice weekly Copaxone (glatiramer) multiple sclerosis drug since a district court found four patents on the product to be invalid.
On Jan. 30, Delaware US District Court Judge Gregory Sleet issued a judgement that the patents on the 40mg dose...





